All About Multiple Sclerosis

More MS news articles for March 2003

Strategic Perspectives: Multiple Sclerosis - Antegren to Challenge Beta-Interferons

http://www.datamonitor.com/~54a0bab7305b41608a83dbac0e9ff28b~//Products/DMV/Free/Report/DMHC1847/020dmhc1847.htm

Publication Date: 21-Feb-2003
Product Code: dmhc1847
Price: $6400

Overview

Introduction

The MS market is led by Biogenís Avonex, which for the first time enjoyed blockbuster revenues in 2002. However, competition is strong, especially from Seronoís Rebif, which is rapidly capturing a large portion of Biogenís US market share. This In-Depth Analysis covers the current and future MS market, and provides key strategic recommendations for existing and potential investors.

Scope

Report Highlights

Improved drug delivery methods of existing treatments is a key unmet need. Due to disappointing trial results, Datamonitor does not expect existing players to launch oral forms of their products before 2008. However, the main short-term opportunity will be launching room temperature and pre-filled pre-mixed syringes.

The US launch of Rebif in particular was a sharp blow to Biogen, as the decision voided Avonexís exclusivity in the US market - the first time the FDA has done this - which entitled Biogen to seven years orphan drug status. Indeed, Biogen has reported a decline in growth rates since the US launch of Rebif.

Reasons to Purchase

Understand the benefits and drawbacks of current treatments for MS patients, in order to target key unmet needs

Enhance your sales forecasting ability and future product positioning through identification of market drivers and key existing and future competitors

Pinpoint hot areas of the market that are not being targeted by competitors

DRIVERS AND TRENDS

The MS market continues to be led by Biogenís Avonex (interferon beta 1a), which for the first time enjoyed blockbuster revenues in 2002. However, competition is strong, especially from Seronoís Rebif (interferon beta 1a), which is rapidly capturing a large portion of Biogenís US market share. This dynamic market is expected to change dramatically over the years, and by 2010 major factors impacting drug sales will include earlier initiation of disease-modifying therapies, the launch of Antegren and other promising novel candidates, and a decreased emphasis on interferons in the treatment protocol of MS. Nevertheless, MS remains an attractive and immature market, with several areas of opportunity. In particular, a large opportunity lies in the chronic progressive MS sector, which constitutes over half of the total MS patient population and lacks approved treatments.

MULTIPLE SCLEROSIS MARKET DEFINITION

How prevalent is MS, how is it treated, and what are the major unmet needs that can be targeted? This chapter covers areas such as MS classification, epidemiology, and introduces the drug treatment of the disease. In addition, the main clinical endpoints of MS are discussed as well as key unmet needs such as induction and maintenance of remission, compliance to treatment, and drugs that work for advanced stages of the disease.

MARKET DYNAMICS

How will the marketing battle between Serono and Biogen to win US supremacy impact the global market? The section analyzes key trends in the global MS market to 2002. Sales trends of MS brands in each of the seven major pharmaceutical markets are analyzed as well as key environmental drivers in these markets. Comprehensive profiles of Rebif, Avonex, Betaseron, Copaxone, and Novantrone are provided, with in-depth analysis of strengths, weaknesses, opportunities and threats.

LIFECYCLE MANAGEMENT

How do exist players expect to continue generating revenues from their products over the forecast period? The purpose of this chapter is to look at new developments to existing drugs in the MS market on a global level. It focuses on the strategies employed by pharmaceutical companies to maximize or extend the product lifecycles of their brands. These strategies include reformulations, expanding indications and expansions into new markets, as well as pricing strategies.

THE FUTURE DECODED

Which are the most promising MS drug candidates in the late stage R&D pipeline? This section analyses key drugs in Phase II and above clinical development. Candidates profiled include Biogen/Elanís Antegren, Serono/IVAXís cladribine, Active Biotechís SAIK-MS, and Schering/Ilex Oncologyís Campath. This section also provides global sales forecasts of current and R&D products to 2010, utilizing Datamonitorís new interactive forecasting tool. Three additional scenario forecasts allow a greater understanding of the MS market, by providing the ability to identify potential opportunities and pitfalls of this relatively young market.

ACTION POINTS

Understand the benefits and drawbacks of current treatments for MS patients, in order to target key unmet needs

Enhance your sales forecasting ability and future product positioning through identification of market drivers and key existing and future competitors

Pinpoint hot areas of the market that are not being targeted by competitors

Improve drug lifecycle management by gaining insight into how current MS products are seeking line extensions and how well these methods will work

Increase your competitive intelligence by accessing assessments of key product performance to 2010
 

© Datamonitor 21-Feb-2003